TrippBio is developing a new, therapeutic application of an FDA-approved drug with a high probability to be proven safe and efficacious in the treatment and prevention of the SARS-CoV-2 virus that causes COVID-19.
Raised to Date: $13,300
Aggregate Commitments $
Equity - Common
Weekly Commitments $
TrippBio, with a post-money valuation of $7.1 million, is raising funds on NetCapital. The company is developing a new therapeutic application of an FDA-approved drug for the treatment and prevention of the SARS-CoV-2 virus. The company believes that the drug TD213 is capable of preventing the host cell from assembling the virus that causes COVID-19. Billy Meadow and Richard Still founded TrippBio in May 2020. The current round of crowdfunding has a minimum raise of $10,000 and a maximum raise of $1,070,000, and the funds will be used for initial clinical trial, development and manufacturing of TD213, marketing and advertising, professional services, and ramp-up clinical trial. TrippBio is well-positioned to help the world combat COVID-19 and other infectious diseases.
UpLyft on Wefunder
UpLyft has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected…
HealtheMed on Wefunder
HealtheMed has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected…
Millennial Fertility Co. on NetCapital
The Millennial Fertility Co. team has been selected as a “Deal to Watch” by KingsCrowd. This distinction is…